SoMex Research & Health
Pvt. Ltd.
+91-141-2504996           
banner11 banner22 banner33 banner44

News & Events


Ribociclib has been granted breakthrough therapy designation for use in combination with tamoxifen or an AI)= as frontline treatment for pre- or perimenopausal women with HR+ HER2– advanced or metasta

(8-January-2018)
Ribociclib has been granted breakthrough therapy designation for use in combination with tamoxifen or an AI)= as frontline treatment for pre- or perimenopausal women with HR+ HER2– advanced or metastatic breast cancer.



Other News